Hydrocortison Strides Pharma (Cyprus)

Hydrocortison Strides Pharma is a prescription oral medication that contains the corticosteroid hydrocortisone as its active ingredient. The product is marketed in the European Union, including Cyprus, and is supplied without a specified strength or dosage form in the public data. Hydrocortison Strides Pharma is classified as a glucocorticoid and is used under medical supervision for conditions requiring glucocorticoid therapy and may be prescribed by qualified healthcare professionals.

Hydrocortison Strides Pharma is indicated for several clinical situations where glucocorticoid activity is required. - Replacement therapy in adrenal insufficiency (e.g., primary or secondary adrenal failure). - Management of acute exacerbations of inflammatory disorders such as rheumatoid arthritis. - Treatment of severe allergic reactions when systemic corticosteroid effect is needed. - Adjunct therapy for certain autoimmune diseases, including systemic lupus erythematosus. - Short‑term control of skin or mucosal inflammation when oral therapy is preferred.

Oral hydrocortisone may cause a range of adverse reactions, varying in frequency and severity. Common: - Increased appetite and modest weight gain, often observed after several weeks. - Fluid retention leading to mild peripheral edema, most noticeable in the ankles. - Elevated blood glucose levels, which may necessitate closer monitoring in diabetic patients. - Mood alterations such as irritability, anxiety, or difficulty sleeping during treatment. Serious: - Suppression of the hypothalamic‑pituitary‑adrenal axis, which can cause adrenal insufficiency if the drug is stopped suddenly. - Increased susceptibility to severe infections because of systemic immunosuppression. - Decreased bone mineral density resulting in osteoporosis or a higher risk of fractures with long‑term use. - Development of peptic ulcer disease or gastrointestinal bleeding, particularly when combined with NSAIDs or anticoagulants.

When prescribing Hydrocortison Strides Pharma, clinicians should consider several precautionary measures to ensure safe use. - Assess baseline adrenal function before initiating therapy, especially in patients with known endocrine disorders. - Use the lowest effective dose for the shortest duration to minimize systemic effects. - Monitor blood glucose and blood pressure regularly in patients with diabetes or hypertension. - Evaluate bone health periodically, particularly for long‑term users, and consider calcium/vitamin D supplementation. - Avoid abrupt discontinuation; taper the dose gradually to prevent adrenal crisis. - Caution in patients with active infections; weigh benefits against potential immunosuppression. - Review concomitant use of NSAIDs or anticoagulants due to increased gastrointestinal risk.

Hydrocortison Strides Pharma can interact with other medicines, altering its efficacy or safety profile. Avoid: - Strong CYP3A4 inducers such as rifampin, which may reduce hydrocortisone plasma concentrations. - High‑dose systemic corticosteroids from other sources, increasing risk of glucocorticoid excess. Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and anticoagulants, which raise the chance of gastrointestinal bleeding. - Antidiabetic agents, as hydrocortisone may raise blood glucose and require dose adjustments. - Antihypertensive medications, because fluid retention can diminish their effectiveness. - Vaccines containing live attenuated organisms, due to possible reduced immune response.